Zacks Investment Research upgraded shares of Iqvia (NYSE:IQV) from a sell rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “IQVIA Holdings Inc. is a provider of information, innovative technology solutions and contract research services focused on using data and science which offer healthcare clients find better solutions for their patients. IQVIA Holdings Inc., formerly known as Quintiles IMS Holdings, Inc., is based in DURHAM, United States. “
A number of other equities analysts also recently issued reports on IQV. JPMorgan Chase raised their price objective on Iqvia from $115.00 to $120.00 and gave the stock an overweight rating in a research report on Thursday, February 15th. ValuEngine upgraded Iqvia from a hold rating to a buy rating in a research report on Tuesday, February 20th. Royal Bank of Canada set a $118.00 price objective on Iqvia and gave the stock a buy rating in a research report on Thursday, February 15th. SunTrust Banks upgraded Iqvia from a hold rating to a buy rating in a research report on Wednesday, March 7th. Finally, Mizuho set a $97.00 price objective on Iqvia and gave the stock a hold rating in a research report on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $110.47.
Iqvia (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing the Zacks’ consensus estimate of $1.34 by ($0.02). Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the previous year, the business posted $1.09 earnings per share. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. equities analysts predict that Iqvia will post 5.02 EPS for the current year.
In other Iqvia news, insider Robert Parks sold 896 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $105.73, for a total value of $94,734.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James H. Erlinger III sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $100.00, for a total value of $1,000,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,712 shares of company stock valued at $1,176,334. 6.00% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in IQV. Winslow Evans & Crocker Inc. acquired a new stake in Iqvia in the fourth quarter valued at approximately $123,000. Focused Wealth Management Inc acquired a new stake in Iqvia in the fourth quarter valued at approximately $166,000. Valeo Financial Advisors LLC acquired a new stake in Iqvia in the fourth quarter valued at approximately $170,000. IFP Advisors Inc acquired a new stake in Iqvia in the fourth quarter valued at approximately $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in Iqvia in the fourth quarter valued at approximately $209,000. 92.35% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://weekherald.com/2018/04/19/iqvia-iqv-upgraded-to-hold-at-zacks-investment-research.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.